Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc. announced the grant of inducement equity awards to four newly hired non-executive employees. The awards include non-qualified stock options to purchase 20,050 shares of common stock at an exercise price of $19.67 per share, and restricted stock units for an aggregate of 4,400 shares. These awards, totaling 24,450 shares, were granted under the Monte Rosa Therapeutics, Inc. 2026 Inducement Plan as a material inducement for their employment.

Monte Rosa Therapeutics, a clinical-stage biotechnology company, announced its management will participate in two upcoming investor conferences. The company will present at the TD Cowen 7th Annual Oncology Innovation Summit on May 27, 2026, and the Jefferies Global Healthcare Conference on June 4, 2026. Webcasts of both fireside chats will be available on the company's investor relations website, with archived versions accessible for 30 days.

Monte Rosa Therapeutics reported a net loss of $44.5 million for the first quarter of 2026, a significant decline from the net income of $46.9 million in the same period last year. This was primarily driven by a sharp decrease in collaboration revenue to $4.2 million from $84.9 million year-over-year, despite an increase in research and development expenses. The company bolstered its liquidity with $324.3 million in net proceeds from an underwritten public offering, bringing its total cash, cash equivalents, and marketable securities to $666.2 million as of March 31, 2026, which is expected to fund operations for at least 12 months.

Monte Rosa Therapeutics reported a net loss of $44.5 million for Q1 2026, a shift from a net income of $46.9 million in Q1 2025, with collaboration revenue decreasing to $4.2 million. Despite this, the company announced significant pipeline advancements, including positive interim data for MRT-8102 and MRT-2359, with multiple Phase 2 studies planned for these programs and MRT-6160. A strong balance sheet, bolstered by a $345 million public offering in January, provides a cash runway into 2029.

Monte Rosa Therapeutics, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 11, 2026. Shareholders will vote on the election of three Class II director nominees and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The record date for stockholders entitled to vote is April 16, 2026.

Monte Rosa Therapeutics, Inc. (GLUE) announced its 2026 Annual Meeting of Stockholders will be held virtually on June 11, 2026, at 8:30 a.m. Eastern Time. Stockholders will vote on the election of three Class II director nominees and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The board of directors recommends a vote "FOR" both proposals.